NCT07190534Not yet recruiting
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- No phase declared
- Sponsor
- Erasmus Medical Center
- Participants (registry)
- 50
- Start
- November 2025 (planned)
- Primary completion
- November 2026 (planned)
- Study completion
- May 2027 (planned)
- Last registry update
- September 2025
- Countries
- Netherlands
Conditions studied: Frontal Fibrosing Alopecia, Cicatricial Alopecia
Interventions: Hydroxychloroquine (HCQ), Plaquenil, Methotrexate (MTX), MTX
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.